Alberto
Cordero
Universidade de Santiago de Compostela
Santiago de Compostela, EspañaPublicacións en colaboración con investigadores/as de Universidade de Santiago de Compostela (11)
2024
2023
-
Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real World—MEMOGAL Study
American Journal of Cardiovascular Drugs, Vol. 23, Núm. 5, pp. 583-593
-
Differences in weight loss and safety between the glucagon-like peptide-1 receptor agonists: A non-randomized multicenter study from the titration phase
Primary Care Diabetes, Vol. 17, Núm. 4, pp. 366-372
-
Effect of dapagliflozin on COVID-19 infection and risk of hospitalization
The Journal of antimicrobial chemotherapy, Vol. 78, Núm. 9, pp. 2335-2342
-
Patients With High Cardiovascular Risk as Candidates to Bempedoic Acid, After Treatment With Statins, Ezetimibe and PCSK9 Inhibitors: An Estimation and Cost-Effectiveness Analysis
Journal of cardiovascular pharmacology, Vol. 81, Núm. 1, pp. 70-75
2022
-
Effect of PCSK9 inhibitors on remnant cholesterol and lipid residual risk: The LIPID-REAL registry
European Journal of Clinical Investigation, Vol. 52, Núm. 12
-
Sex Differences in Low-Density Lipoprotein Cholesterol Reduction with PCSK9 Inhibitors in Real-world Patients: The LIPID-REAL Registry
Journal of Cardiovascular Pharmacology, Vol. 79, Núm. 4, pp. 523-529
2021
-
New-onset heart failure after acute coronary syndrome in patients without heart failure or left ventricular dysfunction
Revista Espanola de Cardiologia, Vol. 74, Núm. 6, pp. 494-501
2020
-
Prediction of major adverse cardiac, cerebrovascular events in patients with diabetes after acute coronary syndrome
Diabetes and Vascular Disease Research, Vol. 17, Núm. 1
2016
-
Tendencias en factores de riesgo y tratamientos de pacientes con cardiopatía isquémica estable atendidos en consultas de cardiología entre 2006 y 2014
Revista Espanola de Cardiologia, Vol. 69, Núm. 4, pp. 401-407